ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ulotaront

Also written as “SEP-363856”, “SEP-363856 75mg” and “SEP363856”.

Its studies are mostly in Schizophrenia · Generalized Anxiety Disorder · Depressive Disorder, Major · Parkinson Disease · Narcolepsy, led by 2 companies.

Drug pageSEP-363856: every studyAll 30 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 26, 201930 company-led studies, 5 open or runningNext primary completion: Mar 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka265 open or runningphase 3since Aug 26, 2019Oct 24, 2013Mar 2028phase 3 · NCT07225712
Sumitomo Pharmaits history only40 open or runningphase 3since Mar 29, 2021Nov 22, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Otsuka only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Oct 24, 2013.

  1. Oct 2, 2019Phase 3 study in SchizophreniaNCT04115319 · 305 enrolled · United States, Romania, Russia and more
  2. Apr 27, 2020Phase 1 study in SchizophreniaNCT04369391 · 150 enrolled · United States
  3. Dec 19, 2020Named ulotarontINNProposed as its International Nonproprietary Name in WHO's List 124 · before, SEP-363856, SEP363856
  4. Apr 26, 2021Phase 1 study in SchizophreniaNCT04865835 · 21 enrolled · United States
  5. Aug 10, 2021Phase 1 study in NarcolepsyNCT05015673 · 18 enrolled · United States
  6. May 24, 2022Phase 1 study in SchizophreniaNCT05402111 · 31 enrolled · United States
  7. Jul 6, 2022Phase 1 study in SchizophreniaNCT05463770 · 15 enrolled · United States
  8. Aug 15, 2022Phase 1 study in SchizophreniaNCT05542264 · 19 enrolled · United States
  9. Oct 10, 2022Phase 2 study in Depressive Disorder, MajorNCT05593029 · 929 enrolled · United States, Bulgaria, Canada and more
  10. Nov 16, 2022Phase 3 study in SchizophreniaNCT05628103 · 101 enrolled · United States
  11. Feb 6, 20232 phase 3 studiesNCT05729373, NCT05741528
  12. Apr 27, 2023Phase 1 study in SchizophreniaNCT05848700 · 60 enrolled · United States
  13. Feb 27, 2025Phase 3 study in SchizophreniaNCT06894212 · 538 enrolled · United States, Japan
  14. Nov 5, 2025Phase 3 study in SchizophreniaNCT07225712 · 100 planned · Japan
  15. Aug 6, 20263 phase 3 studies in Generalized Anxiety DisorderNCT07759128, NCT07767903, NCT07786454

Ahead

  1. Mar 2028Primary completion: phase 3 study in SchizophreniaNCT07225712
  2. Oct 25, 2028Primary completion: phase 3 study in Generalized Anxiety DisorderNCT07767903
  3. Dec 6, 2028Primary completion: phase 3 study in Generalized Anxiety DisorderNCT07759128
  4. May 26, 2029Primary completion: phase 3 study in Generalized Anxiety DisorderNCT07786454

TargetBeta

HTR1A →TAAR1 →read by rule
“Serotonin 1a (5-HT1a) receptor agonist; Trace amine-associated receptor 1 agonist”ChEMBL 37, by rule

Studies

All 26 Otsuka leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07786454Generalized Anxiety Disorder · United States3RecruitingMay 26, 20291,120
NCT07767903Generalized Anxiety Disorder · United States3RecruitingOct 25, 2028384
NCT07759128Generalized Anxiety Disorder · United States3RecruitingDec 6, 2028576
NCT07225712Schizophrenia · Japan3RecruitingMar 2028100
NCT06894212Schizophrenia · United States, Japan3Active, not recruitingOct 20, 2026538
NCT05848700Schizophrenia · United States1CompletedMar 15, 202460
NCT05741528Schizophrenia · United States3CompletedSep 23, 202475
NCT05729373Generalized Anxiety Disorder · United States, Bulgaria, Estonia and more3CompletedSep 26, 2025434
NCT05628103Schizophrenia · United States3CompletedApr 1, 2024101
NCT05593029Depressive Disorder, Major · United States, Bulgaria, Canada and more2CompletedNov 6, 2025929
NCT05542264Schizophrenia · United States1CompletedFeb 12, 202419
NCT05463770Schizophrenia · United States1CompletedAug 22, 202315
NCT05402111Schizophrenia · United States1CompletedSep 27, 202331
NCT05015673Narcolepsy · United States1CompletedMay 26, 201518
NCT04865835Schizophrenia · United States1CompletedMay 3, 202221
NCT04369391Schizophrenia · United States1CompletedNov 10, 2020150
NCT04115319Schizophrenia · United States, Romania, Russia and more3CompletedDec 30, 2022305
NCT04109950Schizophrenia · United States, Bulgaria, Colombia and more3TerminatedNov 9, 2023463
NCT04092686Schizophrenia · United States, Bulgaria, Croatia and more3CompletedJun 14, 2023464
NCT04072354Schizophrenia · United States, Bulgaria, Colombia and more3CompletedMay 12, 2023463
NCT04038957Schizophrenia · United Kingdom1CompletedJun 6, 202322
NCT02970929Schizophrenia · United States, Hungary, Romania and more2CompletedJan 29, 2019157
NCT02969369Parkinson Disease Psychosis · United States2CompletedApr 20, 202039
NCT02969382Schizophrenia · United States, Hungary, Romania and more2CompletedJul 31, 2018245
NCT01994473Schizophrenia · United States1CompletedDec 201448
NCT01972711Schizophrenia · United Kingdom1CompletedJul 2015105

How it is read

Names in the registry

  • “SEP-363856”, 24 entries
  • “SEP-363856 75mg”, 2 entries
  • “SEP363856”, 2 entries
  • “SEP-363856 100mg”, 1 entry
  • “SEP-363856 50mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.